TY - JOUR
T1 - Intracellular amyloid formation in muscle cells of A-transgenic Caenorhabditis elegans
T2 - Determinants and physiological role in copper detoxification
AU - Minniti, Alicia N.
AU - Rebolledo, Daniela L.
AU - Grez, Paula M.
AU - Fadic, Ricardo
AU - Aldunate, Rebeca
AU - Volitakis, Irene
AU - Cherny, Robert A.
AU - Opazo, Carlos
AU - Masters, Colin
AU - Bush, Ashley I.
AU - Inestrosa, Nibaldo C.
N1 - Funding Information:
Some nematode strains used in this work were provided by the Caenorhabditis Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR). This work was supported by the International Copper Association (ICA, New York, N.Y.), FONDAP-Biomedicine grant N° 13980001, Millennium Institute of Fundamental and Applied Biology (MIFAB), the Center for Aging and Regeneration (CARE), PFB 12/2007, Base Financing Program for Scientific and Technological Centers of Excellence, CONICYT, the Alzheimer's Association, the NHMRC and the NIA (R01AG12686 to AIB).
PY - 2009
Y1 - 2009
N2 - Background: The amyloid -peptide is a ubiquitous peptide, which is prone to aggregate forming soluble toxic oligomers and insoluble less-toxic aggregates. The intrinsic and external/environmental factors that determine A aggregation in vivo are poorly understood, as well as the cellular meaning of this process itself. Genetic data as well as cell biological and biochemical evidence strongly support the hypothesis that A is a major player in the onset and development of Alzheimer's disease. In addition, it is also known that A is involved in Inclusion Body Myositis, a common myopathy of the elderly in which the peptide accumulates intracellularly. Results: In the present work, we found that intracellular A aggregation in muscle cells of Caenorhabditis elegans overexpressing A peptide is affected by two single amino acid substitutions, E22G (Arctic) and V18A (NIC). Both variations show decrease intracellular amyloidogenesis compared to wild type A. We show that intracellular amyloid aggregation of wild type A is accelerated by Cu2+ and diminished by copper chelators. Moreover, we demonstrate through toxicity and behavioral assays that A-transgenic worms display a higher tolerance to Cu2+ toxic effects and that this resistance may be linked to the formation of amyloid aggregates. Conclusion: Our data show that intracellular A amyloid aggregates may trap excess of free Cu2+ buffering its cytotoxic effects and that accelerated intracellular A aggregation may be part of a cell protective mechanism.
AB - Background: The amyloid -peptide is a ubiquitous peptide, which is prone to aggregate forming soluble toxic oligomers and insoluble less-toxic aggregates. The intrinsic and external/environmental factors that determine A aggregation in vivo are poorly understood, as well as the cellular meaning of this process itself. Genetic data as well as cell biological and biochemical evidence strongly support the hypothesis that A is a major player in the onset and development of Alzheimer's disease. In addition, it is also known that A is involved in Inclusion Body Myositis, a common myopathy of the elderly in which the peptide accumulates intracellularly. Results: In the present work, we found that intracellular A aggregation in muscle cells of Caenorhabditis elegans overexpressing A peptide is affected by two single amino acid substitutions, E22G (Arctic) and V18A (NIC). Both variations show decrease intracellular amyloidogenesis compared to wild type A. We show that intracellular amyloid aggregation of wild type A is accelerated by Cu2+ and diminished by copper chelators. Moreover, we demonstrate through toxicity and behavioral assays that A-transgenic worms display a higher tolerance to Cu2+ toxic effects and that this resistance may be linked to the formation of amyloid aggregates. Conclusion: Our data show that intracellular A amyloid aggregates may trap excess of free Cu2+ buffering its cytotoxic effects and that accelerated intracellular A aggregation may be part of a cell protective mechanism.
UR - http://www.scopus.com/inward/record.url?scp=60349131260&partnerID=8YFLogxK
U2 - 10.1186/1750-1326-4-2
DO - 10.1186/1750-1326-4-2
M3 - Article
AN - SCOPUS:60349131260
SN - 1750-1326
VL - 4
JO - Molecular Neurodegeneration
JF - Molecular Neurodegeneration
IS - 1
M1 - 2
ER -